[HTML][HTML] Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH …
KA Martin, J Beyer‐Westendorf, BL Davidson… - Journal of Thrombosis …, 2021 - Elsevier
Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC …
KA Martin, J Beyer-Westendorf… - Journal of …, 2021 - scholars.northwestern.edu
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC …
KA Martin, J Beyer-Westendorf… - … of thrombosis and …, 2021 - pubmed.ncbi.nlm.nih.gov
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: updated communication from the ISTH SSC …
KA Martin, J Beyer-Westendorf… - Journal of …, 2021 - scholarlypublications …
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC …
KA Martin, J Beyer‐Westendorf… - … of Thrombosis and …, 2021 - Wiley Online Library
Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC …
KA Martin, J Beyer-Westendorf… - … of Thrombosis and …, 2021 - europepmc.org
Although direct-acting oral anticoagulants (DOACs) have widespread first-line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
Use of direct oral anticoagulants in patients with obesity for treatment and prevention of venous thromboembolism: Updated communication from the ISTH SSC …
KA Martin, J Beyer‐Westendorf, BL Davidson… - Journal of Thrombosis …, 2021 - jthjournal.org
Although direct‐acting oral anticoagulants (DOACs) have widespread first‐line use for
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …
treatment and prevention of venous thromboembolism (VTE), uncertainty remains regarding …